GoodRx (GDRX) FDA Approvals $3.73 +0.01 (+0.27%) Closing price 08/14/2026 04:00 PM EasternExtended Trading$3.65 -0.08 (-2.17%) As of 08/14/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share FDA Events Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock GoodRx's Drug in the FDA Approval ProcessThis section highlights FDA-related milestones and regulatory updates for drugs developed by GoodRx (GDRX). Over the past two years, GoodRx has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as Zepbound. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. Zepbound FDA Regulatory Events Zepbound is a drug developed by GoodRx for the following indication: for chronic weight management in adults with obesity. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy. Provided Update - March 6,2026Provided Update Drug: ZepboundAnnounced Date: March 6, 2026Indication: for chronic weight management in adults with obesityAnnouncementGoodRx announced employer-sponsored access to Zepbound® (tirzepatide) KwikPen® (for single-patient-use) through GoodRx Employer Direct.AI SummaryGoodRx announced a collaboration with Eli Lilly to offer employer-sponsored access to Zepbound® (tirzepatide) KwikPen® (single-patient-use) through GoodRx Employer Direct. The program lets self-insured employers subsidize Lilly’s discounted $449 medication price so employees face lower out-of-pocket costs for Zepbound KwikPen. Employer contributions are applied directly to the medication cost, and GoodRx combines the manufacturer’s discounted pricing with employer funding in real time at checkout. The service also offers optional telemedicine to help with prescribing and fulfillment, aiming to simplify how employees obtain and pay for the medicine. GoodRx describes the model as a scalable, transparent way for employers to manage rising demand for GLP-1 obesity treatments while helping employees afford therapy. The partnership is positioned to expand access to Zepbound while giving employers a predictable way to support medication costs.Read Announcement GoodRx FDA Events - Frequently Asked Questions Has GoodRx received FDA approval? As of now, GoodRx (GDRX) has not received any FDA approvals for its therapy in the last two years. What drugs has GoodRx submitted to the FDA? In the past two years, GoodRx (GDRX) has reported FDA regulatory activity for Zepbound. What is the most recent FDA event for GoodRx? The most recent FDA-related event for GoodRx occurred on March 6, 2026, involving Zepbound. The update was categorized as "Provided Update," with the company reporting: "GoodRx announced employer-sponsored access to Zepbound® (tirzepatide) KwikPen® (for single-patient-use) through GoodRx Employer Direct." What conditions do GoodRx's current drugs treat? Currently, GoodRx has one therapy (Zepbound) targeting the following condition: for chronic weight management in adults with obesity. More FDA Event Resources from MarketBeat FDA Calendars Recent FDA Drug Approval Calendar Upcoming FDA Events & PDUFA Dates Calendar Companies With Recent FDA Events Fate Therapeutics FDA EventsLantheus FDA EventsAgenus FDA EventsBiomea Fusion FDA EventsMiNK Therapeutics FDA EventsRigel Pharmaceuticals FDA EventsBristol Myers Squibb FDA EventsAligos Therapeutics FDA EventsAnnexon FDA EventsAlterity Therapeutics FDA EventsCullinan Therapeutics FDA EventsDefinium Therapeutics FDA EventsFreenome FDA EventsAthira Pharma FDA EventsNeurocrine Biosciences FDA Events FDA Event Stage Terminology & Abbreviation Guide NDA: New Drug Application ANDA: Abbreviated New Drug Application sNDA: Supplemental New Drug Application BLA: Biologics License Application sBLA: Supplemental Biologics License Application FDA Approved: Approved by the FDA EMA: European Medicines Agency CE Mark: European Union Certification NMPA: China National Medical Products Administration MHLW: Japanese Ministry of Health FDA Meeting: Consultation with FDA Pre-IND: Pre-Investigational New Drug Meeting Breakthrough Therapy: Special FDA designation for promising therapies Fast Track: Accelerated FDA approval pathway Orphan Drug: Designation for rare disease treatments RPD: Rare Pediatric Disease Designation RMAT: Regenerative Medicine Advanced Therapy DSMB Review: Data Safety Monitoring Board Review IDMC Review: Independent Data Monitoring Committee MAA: MHRA Marketing Authorization Application RTF: Refusal to File (Rejected Application) 510(k): FDA Clearance for Medical Devices Rolling Submission: Staggered regulatory review process Related Companies Heartflow FDA Events Aclarion FDA Events ACADIA Pharmaceuticals FDA Events Dyne Therapeutics FDA Events Veradermics FDA Events Edgewise Therapeutics FDA Events Stock Lists Biotechnology StocksCompare Biotech StocksCompare Healthcare StocksCompare Pharmaceutical StocksHealthcare Stocks FDA progress for NASDAQ:GDRX last updated on 3/6/2026 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data. From Our PartnersHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredA Dark Day Is Coming to AmericaKeith Kaplan, CEO of TradeSmith, has spent more than $17 million studying AI since 2022. He says a major shift...TradeSmith | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...Paradigm Press | SponsoredThe dollar reset no one told you aboutPorter Stansberry says a dollar reset is underway - one that has happened only once before in America's 250-ye...Porter & Company | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredWall Street is staring at the wrong AI tradeAnthropic just signed a 9.1 billion dollar, 20 year data center agreement covering 191 megawatts of capacity, ...The Oxford Club | SponsoredWhat is Trump’s decade-long obsession?No president has moved markets like Trump, adding and erasing trillions in value seemingly at will. Analyst...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GoodRx Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GoodRx With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Provided Update - March 6,2026Provided Update Drug: ZepboundAnnounced Date: March 6, 2026Indication: for chronic weight management in adults with obesityAnnouncementGoodRx announced employer-sponsored access to Zepbound® (tirzepatide) KwikPen® (for single-patient-use) through GoodRx Employer Direct.AI SummaryGoodRx announced a collaboration with Eli Lilly to offer employer-sponsored access to Zepbound® (tirzepatide) KwikPen® (single-patient-use) through GoodRx Employer Direct. The program lets self-insured employers subsidize Lilly’s discounted $449 medication price so employees face lower out-of-pocket costs for Zepbound KwikPen. Employer contributions are applied directly to the medication cost, and GoodRx combines the manufacturer’s discounted pricing with employer funding in real time at checkout. The service also offers optional telemedicine to help with prescribing and fulfillment, aiming to simplify how employees obtain and pay for the medicine. GoodRx describes the model as a scalable, transparent way for employers to manage rising demand for GLP-1 obesity treatments while helping employees afford therapy. The partnership is positioned to expand access to Zepbound while giving employers a predictable way to support medication costs.Read Announcement
